TWD
TARS icon

True Wealth Design’s Tarsus Pharmaceuticals TARS Stock Holding History

True Wealth Design’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$693 Hold
11
– – ﹤0.01% 2099
2026
Q1 		$772 Hold
11
– – ﹤0.01% 1897
2025
Q4 		$901 Hold
11
– – ﹤0.01% 1746
2025
Q3 		$654 Buy
11
+4
+57% +$197 ﹤0.01% 1915
2025
Q2 		$284 Buy
+7
New +$315 ﹤0.01% 1964

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

True Wealth Design's TARS Position: Q2 2026 in Review

True Wealth Design held its Tarsus Pharmaceuticals (TARS) position steady in Q2 2026 at 11 shares worth $693. The position accounts for ﹤0.01% of the portfolio, ranked #2099.

True Wealth Design first reported a position in TARS in Q2 2025 and has held it in 5 quarters since. The position peaked at $901 in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • True Wealth Design held 11 shares of Tarsus Pharmaceuticals worth $693 as of Q2 2026.
  • True Wealth Design left its Tarsus Pharmaceuticals share count unchanged in Q2 2026.
  • Tarsus Pharmaceuticals made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #2099 holding.
  • True Wealth Design first reported a position in Tarsus Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • True Wealth Design's Tarsus Pharmaceuticals position peaked at $901 in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.